Navneet S Majhail
Overview
Explore the profile of Navneet S Majhail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
268
Citations
4712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hickey C, Zhang M, Allbee-Johnson M, Romee R, Majhail N, Al Malki M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):174.e1-174.e12.
PMID: 39755256
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been...
2.
Battiwalla M, Tees M, Tees M, Flinn I, Flinn I, Pantin J, et al.
Blood Adv
. 2024 Oct;
9(2):429-435.
PMID: 39418599
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended...
3.
Lucena M, Gaffney K, Urban T, Forbes C, Srinivas P, Majhail N, et al.
Clin Hematol Int
. 2024 May;
6(1):59-66.
PMID: 38817693
Febrile neutropenia (FN) is an oncologic emergency frequently encountered in hematopoietic cell transplant (HCT) and chimeric antigen receptor (CAR) T-cell therapy patients, which requires immediate initiation of broad-spectrum antibiotics. Data...
4.
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, et al.
Blood
. 2024 Apr;
143(26):2722-2734.
PMID: 38635762
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by...
5.
Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y, et al.
Bone Marrow Transplant
. 2024 Feb;
59(6):717-741.
PMID: 38413823
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the volume of HCT performed annually continues to rise. Parallel improvements in HCT techniques...
6.
Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y, et al.
Transplant Cell Ther
. 2024 Feb;
30(4):349-385.
PMID: 38413247
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the number of HCTs performed annually continues to rise. Parallel improvements in HCT techniques...
7.
Ramirez P, Atsuta Y, AlSeraihy A, Okamoto S, Teshima T, Aljurf M, et al.
Transplant Cell Ther
. 2024 Feb;
30(5):468-474.
PMID: 38346644
We provide a summary of the 4th ASTCT International Workshop with presentations from experts from Chile ("Setting Up a Transplantation Program in Chile," by Dr Pablo Ramirez), Saudi Arabia ("Developing...
8.
Majhail N, Miller B, Dean R, Manghani R, Shin H, Sivaraman S, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):749.e1-749.e5.
PMID: 37703995
A phase 3 trial (ClincialTrials.gov identifier NCT02730299) of omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy manufactured from a single umbilical cord blood (UCB) unit, showed faster hematopoietic recovery, reduced...
9.
Aleixo G, Wei W, Chen P, Gandhi N, Anwer F, Dean R, et al.
Bone Marrow Transplant
. 2023 Sep;
58(12):1384-1389.
PMID: 37699993
Recently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body composition parameters and outcomes has not been...
10.
Auletta J, Khera N, Demartino P, Kelkar A, Yusuf R, Davies S, et al.
Transplant Cell Ther
. 2023 Aug;
29(11):713-720.
PMID: 37579920
The American Society for Transplantation and Cellular Therapy (ASTCT) and the National Marrow Donor Program (NMDP) formed the ACCESS Initiative to address and reduce barriers to hematopoietic cell transplantation (HCT)...